Please use this identifier to cite or link to this item:
|Title:||Biomedical application of electroporation: electrochemotherapy and electrogene therapy||Authors:||Čemažar, Maja
Meulenberg, Cecil W.
|Keywords:||electrochemotherapy; electrogene therapy,electroporation; preparation of plasmids without genes for antibiotic resistance||Issue Date:||2014||Publisher:||EUT Edizioni Università di Trieste||Source:||Maja Čemažar, Vesna Todorović, Cecil W. Meulenberg, Nataša Tešić, Andrej Cor, Biomedical application of electroporation: electrochemotherapy and electrogene therapy, in Sabina Passamonti (ed.), The Partners and the Objectives of Trans2Care, an Italy-Slovenia cross-border network of science and healthcare institutions, EUT - Edizioni Università di Trieste, 2014, pp. 123-127||Abstract:||
Electroporation refers to exposure of cells to external electric field thatresults in transiently or permanently increased permeability of cell membranes. Cancer treatment, where local application of electroporation to tumor nodules is combined with chemotherapeutic drugs bleomycin or cisplatin is called electrochemotherapy. The antitumor effectiveness of electrochemotherapy is primarily based on direct killing of tumor cells due to the increased chemotherapeutic drug uptake, but other mechanisms, such as vascular disrupting action was also demonstrated. Our group is involved in elucidating the underlying mechanism of vascular disrupting action by studying the changes in cytoskeletal proteins after electrochemotherapy in endothelial cells by immunocytochemistry. In addition, metastatic potential and global changes in gene expression of melanoma cells that survived electrochemotherapy were also studied, demonstrating that metastatic potential of cells is not changed and that a very low percentage of genes are down or up regulated after electrochemotherapy, which further supports its safe use in the clinical setting. Another application of electroporation is delivery of plasmid DNA into the cells for gene therapy. Our group is involved in preparation of plasmid DNA with tissue specific promoters and without genes for antibiotic resistance, thus enabling safe use of gene therapy in line with USA Food and Drug Administration (FDA) and European medicines Agency (EMA) recommendations.
|Appears in Collections:||Trans2Care, 2012. The Partnership and the Objectives of Trans2Care, an Italy-Slovenia cross-border network of science|
Show full item record
Files in This Item:
Page view(s) 50788
checked on Sep 27, 2022
checked on Sep 27, 2022
This item is licensed under a Creative Commons License